AC Immune Initiates Final Cohort in Phase 1b/2 ABATE Trial for Anti-Abeta Alzheimer's Treatment

Key Takeaways

• AC Immune initiated treatment of first patient in final Cohort AD4 of the ABATE trial, triggering a $12 million milestone payment
• The trial evaluates anti-Abeta active immunotherapy as a potential precision prevention approach for Alzheimer’s disease
• Data from the first three cohorts (AD1, AD2, AD3) after 12 months of treatment is expected in Q2 2026

---

AC Immune SA (NASDAQ: ACIU) announced the initiation of its final patient cohort in the ongoing Phase 1b/2 ABATE trial, marking a significant milestone in the development of anti-Abeta active immunotherapy for Alzheimer’s disease treatment.

The clinical-stage biopharmaceutical company began treating the first patient in Cohort AD4, triggering a $12 million milestone payment. This advancement represents the culmination of the ABATE trial’s patient enrollment phase, which has been evaluating the safety and efficacy of AC Immune’s innovative immunotherapy approach.

Precision Prevention Approach

The ABATE trial is designed to assess the potential for precision prevention of neurodegenerative diseases, specifically targeting amyloid-beta proteins that accumulate in Alzheimer’s patients’ brains. This active immunotherapy approach aims to stimulate the patient’s immune system to naturally clear these harmful protein deposits.

Unlike passive immunotherapies that introduce external antibodies, AC Immune’s anti-Abeta active immunotherapy works by training the patient’s immune system to recognize and eliminate amyloid-beta plaques independently. This approach could potentially offer longer-lasting protection with less frequent dosing.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Trial Timeline and Expected Results

The company expects to release comprehensive data from the first three cohorts (AD1, AD2, and AD3) after 12 months of treatment in Q2 2026. These results will be crucial in determining the therapy’s safety profile and preliminary efficacy signals.

The milestone payment reflects confidence from AC Immune’s partners in the trial’s progress and the potential of this novel therapeutic approach. The completion of patient enrollment across all four cohorts positions the company to generate robust clinical data that could support future regulatory submissions.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Implications

With the Alzheimer’s treatment landscape rapidly evolving following recent FDA approvals of amyloid-targeting therapies, AC Immune’s active immunotherapy represents a differentiated approach that could offer advantages in terms of dosing convenience and sustained immune response.

The successful initiation of the final cohort demonstrates AC Immune’s ability to execute complex clinical trials in the competitive neurodegenerative disease space, potentially positioning the company as a key player in next-generation Alzheimer’s treatments.

---

Frequently Asked Questions

What makes AC Immune’s anti-Abeta therapy different from other Alzheimer’s treatments?

AC Immune’s therapy uses active immunotherapy, which trains the patient’s immune system to naturally clear amyloid-beta plaques, potentially offering longer-lasting effects compared to passive antibody treatments that require frequent infusions.

When will AC Immune’s Alzheimer’s treatment be available to patients?

The treatment is currently in Phase 1b/2 trials with data expected in Q2 2026. If successful, additional Phase 3 trials would be needed before potential FDA approval, likely several years away.

What does the $12 million milestone payment indicate about the trial’s progress?

The milestone payment triggered by initiating the final patient cohort demonstrates that AC Immune has met predetermined enrollment and safety benchmarks, indicating positive trial progression and partner confidence in the program.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
• Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial